BCAL Diagnostics Signs Validation Agreement with Sonic USA for Breastest V2
BCAL Diagnostics Signs Validation Agreement with Sonic USA for Breastest V2
BCAL Diagnostics Ltd (ASX: BDX) announced it has signed a validation agreement with Sonic Healthcare USA for its Breastest V2 test. The validation will be conducted at Sonic's CLIA-certified laboratory in Austin, Texas.
Agreement Details
Upon successful validation, Sonic Healthcare USA may negotiate a commercial license for the Breastest Plus Version 2. This partnership marks a significant step for BCAL Diagnostics in expanding the global reach of its potentially revolutionary breast cancer screening test.
About the Company
BCAL Diagnostics is a biotechnology company developing innovative blood tests for early detection of breast cancer. Its flagship product, Breastest V2, is designed as a non-invasive, high-accuracy screening tool.
Impacted Symbols
Symbols affected by this headline and their sentiment signals
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.